Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline
Shots:
- WuXi Bio to receive up front and is eligible for development & commercialization milestones- along with royalties on sales of any potential products commercialized from the panel
- Exelixis get an exclusive license to the panel of mAb against an undisclosed oncology target for biologics applications
- Exelixis leverages WuXi Bio’s integrated technology platforms to develop ADC- bispecific- and certain other novel tumor-targeting biologics applications
Ref: PRNewswire | Image: Exelixis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
